Status:
COMPLETED
Assessment of Rituximab's Immunomodulatory Synovial Effects (The ARISE Study)
Lead Sponsor:
University of California, San Diego
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
Using repeated arthroscopic biopsies of patients with rheumatoid arthritis, the researchers will assess changes in the immune response that occur as a result of treatment with rituximab.
Detailed Description
Using repeated arthroscopic biopsies of patients with rheumatoid arthritis, the researchers will assess changes in the immune response that occur after treatment with rituximab.
Eligibility Criteria
Inclusion
- Active rheumatoid arthritis
- Use of concomitant methotrexate
Exclusion
- Use of disease-modifying anti-rheumatic drugs (DMARDs)/biologics other than methotrexate
- Serious medical conditions that would preclude the use of the treating agent
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2009
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00147966
Start Date
June 1 2008
End Date
December 1 2009
Last Update
March 23 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UCSD CIT
La Jolla, California, United States, 92093